

Serial No.: 09/742,148

Filed: December 19, 2000

combining said cells with an activation inhibiting amount of a compound comprising an oligopeptide of at least 6 amino acids comprising a contiguous sequence of the HLA-B  $\alpha_1$  domain or species analog thereof, wherein amino acids 84 to 86 are YYW (SEQ ID NO: 1);

whereby activation of said cells is inhibited.

N.E.  
2. (amended) Method according to Claim 1, wherein said oligopeptide is of at least 8 amino acids and amino acids 83 to 86 are RYYW (SEQ ID NO: 2).

3. A method according to Claim 2 wherein said oligopeptide comprises at least a total of 6 contiguous amino acids from said HLA-B  $\alpha_1$  domain joined to said tetrad.

4. A method according to Claim 1, wherein said compound is a dimer of said oligopeptide.

5. A method according to Claim 1, wherein at least one of said amino acids is a D-stereoisomer.

6. A method according to Claim 1, wherein said combining is in the presence of a viable solid organ or viable second cells other than CTL and NK cells.

N.E.  
7. (amended) A method of inhibiting activation of CTL and NK cells, said method comprising:

Serial No.: 09/742,148

Filed: December 19, 2000

combining said cells with an activation inhibiting amount of a compound comprising an oligopeptide of at least 6 amino acids, including the triad YYW (SEQ ID NO: 1) and comprising a contiguous sequence of the sequence:

aa<sup>70</sup> aa<sup>71</sup> Q aa<sup>73</sup> aa<sup>74</sup> R aa<sup>76</sup> aa<sup>77</sup> L aa<sup>79</sup> aa<sup>80</sup> aa<sup>81</sup> aa<sup>82</sup> aa<sup>83</sup> Y Y W aa<sup>87</sup> aa<sup>88</sup> aa<sup>89</sup> aa<sup>90</sup> aa<sup>91</sup> (SEQ ID NO: 57).

wherein:

aa<sup>70</sup> is Q, H, S, N or K;

aa<sup>71</sup> is an aliphatic neutral amino acid;

aa<sup>73</sup> is T or A;

aa<sup>74</sup> is Y or H;

aa<sup>76</sup> is aliphatic neutral amino acid;

aa<sup>77</sup> is S or N;

aa<sup>79</sup> is R or G;

aa<sup>80</sup> is T, I, N or an aromatic amino acid;

aa<sup>81</sup> is an aliphatic non-polar amino acid;

aa<sup>82</sup> is R, L or an aromatic amino acid;

aa<sup>83</sup> is G or R;

aa<sup>87</sup> is any amino acid;

aa<sup>88</sup> is an aromatic amino acid or aliphatic amino acid of from 5 to 6 carbon atoms;

aa<sup>89</sup> is any amino acid;

aa<sup>90</sup> is any amino acid; and

aa<sup>91</sup> is any amino acid;

whereby activation of said cells is inhibited.

N.E.  
8. (amended) A method according to Claim 7, wherein said oligopeptide is of at least 8 amino acids, is the dimer thereof, or at least one of the amino acids is the D-stereoisomer and is of the formula:

R V/E N/D L R I A/L L R/E Y Y W Q/D S (SEQ ID NO: 3)

wherein the backslashes intend that either amino acid may be present at that position.

9. A method according to Claim 7, wherein said combining is in the presence of a viable solid organ or cells other than CTL or NK cells.

10. (amended) In a method for transplanting a donor mammalian organ or cells other than as part of a viable organ to a mammalian recipient, which method comprises:

isolating said donor organ or cells from said donor and implanting said donor organ or cells in said recipient, the improvement which comprises at least one of the following steps:

(a) combining said organ or cells prior to implanting in said mammalian recipient with an activation inhibiting amount of a compound comprising an oligopeptide of at least 6 amino

Serial No.: 09/742,148  
Filed: December 19, 2000

acids comprising a contiguous sequence of the HLA-B  $\alpha_1$  domain or species analog thereof, wherein amino acids 84 to 86 are YYW (SEQ ID NO: 1); or

(b) administering to said mammalian recipient in a period extending from prior to subsequent to implanting said donor organ or cells an activation inhibiting amount of a compound comprising an oligopeptide of at least 6 amino acids comprising a contiguous sequence of the HLA-B  $\alpha_1$  domain or species analog thereof, wherein amino acids 84 to 86 are YYW (SEQ ID NO: 1).

N.E.

11. (amended) A method according to Claim 10, wherein said compound is of the formula:

R V/E N/D L R I A/L L R/E Y Y W Q/D S (SEQ ID NO: 3)

wherein the backslashes intend that either amino acid may be present at that position.

12. A method according to Claim 11, wherein said compound is a peptide of not more than 20 amino acids and comprises the amino acid sequence N L R I A L R Y Y W.

---

C3

13. (amended) A compound comprising an oligopeptide of at least 6 amino acids comprising a contiguous sequence of the HLA-B  $\alpha_1$  domain or species analog thereof, wherein amino acids 84 to 86 are YYW (SEQ ID NO: 1).

Serial No.: 09/742,148  
Filed: December 19, 2000

14. (amended) A compound comprising an oligopeptide of at least 8 amino acids comprising the triad YYW (SEQ ID NO: 1) and comprising a contiguous sequence of the sequence:

aa<sup>70</sup> aa<sup>71</sup> Q T aa<sup>74</sup> R aa<sup>76</sup> aa<sup>77</sup> L aa<sup>79</sup> aa<sup>80</sup> aa<sup>81</sup> aa<sup>82</sup> aa<sup>83</sup> Y Y W aa<sup>87</sup> aa<sup>88</sup> aa<sup>89</sup> aa<sup>90</sup> aa<sup>91</sup> (SEQ ID NO: 57).

wherein:

aa<sup>70</sup> is Q, H, S, N or K;

aa<sup>71</sup> is an aliphatic neutral amino acid;

aa<sup>74</sup> is D, Y or H;

aa<sup>76</sup> is E or V;

aa<sup>77</sup> is D, S or N;

aa<sup>79</sup> is R or G;

aa<sup>80</sup> is T, I, N or an aromatic amino acid;

aa<sup>81</sup> is an aliphatic non-polar amino acid;

aa<sup>82</sup> is R, L or an aromatic amino acid;

aa<sup>83</sup> is G or R;

aa<sup>87</sup> is any amino acid;

aa<sup>88</sup> is an aromatic amino acid or aliphatic amino acid of from 5 to 6 carbon atoms;